Figure 2.

TOP1 inhibitor irinotecan boosts SASP expression.

(A and B) UPK10 cells were treated with 10μM cisplatin, 10μM irinotecan, a combination or 10 μM DMXAA for three days and released for three days. Expression of TOP1cc, TOP1, cyclin A, phosphor-p65, total p65, phosphor-p38 MAPK, total p38 MAPK, γH2AX, cGAS, and a loading control β-actin was examined by immunoblot in the sorted non-senescent and senescent cells from the indicated treatment groups (A). Expression of the indicated SASP factors in sorted senescent and non-senescent UPK10 cells from the indicated treatment groups was determined by qRT-PCR (B). (n=3 biologically independent experiments).

(C and D) Secretion of SASP factors under the indicated conditions was determined using an antibody array (C). Examples of changes in the secreted SASP factors were highlighted. The heatmap indicates the fold change (FC) in comparison with the control (Ctrl) UPK10 cells. Relative expression levels per replicate and average fold change differences are shown (D).

Data represent mean ± SEM. p values were calculated using a two-tailed t test. See also Figure S2 and Table S1.